We Just Had An Epiphany
Tag: stock analysis
Oracle Stock (ORCL): Can a $664 Billion Backlog Outrun the AI Capex Bill?
Oracle’s cloud-infrastructure revenue surged 121% as remaining performance obligations reached $664 billion. With Larry Ellison still owning roughly 40%, institutions controlling most of the float and valuation sharply compressed, ORCL looks compelling—but heavy debt, negative free cash flow and an enormous AI buildout make execution everything.
📹 Zoom (ZM): Wall Street Still Thinks It's a Video Company. What If It's Becoming an AI Platform? 🤖
Wall Street still sees Zoom as a pandemic-era video conferencing company.
We think that narrative is becoming outdated.
With a fortress balance sheet, nearly $1.7 billion in annual free cash flow, AI Companion, Zoom Phone, Contact Center and Workvivo, Zoom may quietly be evolving into a broader enterprise communications platform.
🧬 Moderna (NASDAQ: MRNA) Stock Analysis: Why We Still Believe This mRNA Pioneer Is Undervalued
Moderna has already doubled from its 2025 lows, yet we believe the story is still in its early chapters. Science Day confirmed that Moderna is becoming far more than a vaccine company—it's building one of biotechnology's most ambitious programmable medicine platforms.
PayPal (PYPL): A Payment Platform to Bet On? 🤔💳
PayPal (PYPL) shows solid growth, ample cash flow, and impressive stock repurchases, making it a potential value play with room for growth rerating and future gains. Here’s why this fintech giant is still worth considering despite market competition.